Home > News > NUCRYST Pharmaceuticals begins Phase 2 clinical trial
December 4th, 2003
NUCRYST Pharmaceuticals begins Phase 2 clinical trial
Abstract:
NUCRYST Pharmaceuticals Corp., a subsidiary of The Westaim Corporation, today announced that it has
begun its first Phase 2 human clinical trial of a topical cream formulation of its nanocrystalline silver. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and other skin conditions and represents a biological application of nanotechnology.
Source:
PRNewswire
Bookmark:
| Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||